BGI Genomics Balance Sheet Health
Financial Health criteria checks 4/6
BGI Genomics has a total shareholder equity of CN¥10.0B and total debt of CN¥347.5M, which brings its debt-to-equity ratio to 3.5%. Its total assets and total liabilities are CN¥13.3B and CN¥3.3B respectively.
Key information
3.5%
Debt to equity ratio
CN¥347.54m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥4.71b |
| Equity | CN¥9.97b |
| Total liabilities | CN¥3.31b |
| Total assets | CN¥13.28b |
Recent financial health updates
Is BGI Genomics (SZSE:300676) Using Too Much Debt?
Oct 22
Is BGI Genomics (SZSE:300676) A Risky Investment?
Jul 15Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly
Mar 25Recent updates
Is BGI Genomics (SZSE:300676) Using Too Much Debt?
Oct 22BGI Genomics Co., Ltd. (SZSE:300676) Held Back By Insufficient Growth Even After Shares Climb 31%
Oct 01Is BGI Genomics (SZSE:300676) A Risky Investment?
Jul 15Why Investors Shouldn't Be Surprised By BGI Genomics Co., Ltd.'s (SZSE:300676) Low P/S
May 22BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings
Apr 21Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly
Mar 25Financial Position Analysis
Short Term Liabilities: 300676's short term assets (CN¥7.6B) exceed its short term liabilities (CN¥2.9B).
Long Term Liabilities: 300676's short term assets (CN¥7.6B) exceed its long term liabilities (CN¥436.6M).
Debt to Equity History and Analysis
Debt Level: 300676 has more cash than its total debt.
Reducing Debt: 300676's debt to equity ratio has increased from 0% to 3.5% over the past 5 years.
Debt Coverage: 300676's debt is well covered by operating cash flow (24.1%).
Interest Coverage: Insufficient data to determine if 300676's interest payments on its debt are well covered by EBIT.